 |
23 Diseases |  |
0 Trials |
|
0 Trials |  |
18 News |  |
- SAR445399 / Sanofi
SAR445399 () - Nov 6, 2023 - Abstract #ISDS2023ISDS_354;
Furthermore, an anti-murine surrogate of SAR445399 alleviates disease and inflammation in an Imiquimod-induced skin inflammation model with superior efficacy than IL-1 blockade alone. In summary, SAR445399 is a broad IL-1 pathway drug hitting 3 birds with 1 stone and is uniquely positioned to potentially raising the efficacy ceiling where a single agent therapy may not be fully efficacious in dermatology or other immunology areas.
- | Review, Journal: Systematic review of immunomodulatory therapies for hidradenitis suppurativa. (Pubmed Central) - Jun 14, 2019
Biologics used in smaller cohorts include canakinumab, golimumab and rituximab...Different clinical measurement scores and endpoints used to make direct comparison difficult. Longitudinal surveillance and pooled registry data are paramount to evaluate the long-term safety profile and efficacy of therapy.
- AMG 108 / AstraZeneca
Enrollment change: A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 6, 2018
P2, N=0, Withdrawn, Sponsor: Amgen
Longitudinal surveillance and pooled registry data are paramount to evaluate the long-term safety profile and efficacy of therapy. N=200 --> 0
- || AMG 108 / AstraZeneca
Trial primary completion date: Long-Term Assessment of Safety and Physical Function With AMG 108 in RA (clinicaltrials.gov) - Dec 13, 2016
P2, N=690, Completed, Sponsor: Amgen
N=200 --> 0 Trial primary completion date: Jan 2009 --> Jun 2008
- |||| AMG 108 / AstraZeneca
Trial completion: Treatment for Patients With Osteoarthritis (OA) (clinicaltrials.gov) - Feb 27, 2016
P2, N=160, Completed, Sponsor: Amgen
Trial primary completion date: Jan 2009 --> Jun 2008 Active, not recruiting --> Completed
- |||| AMG 108 / AstraZeneca
Trial completion, Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Nov 18, 2014
P2a, N=224, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 224
- ||| AMG 108 / AstraZeneca
Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Oct 2, 2014
P2a, N=100, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=100 --> 224 N=224 --> 100
- ||| AMG 108 / AstraZeneca
Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 23, 2014
P2a, N=224, Active, not recruiting, Sponsor: AstraZeneca
N=224 --> 100 N=100 --> 224
- ||| AMG 108 / AstraZeneca
Enrollment closed: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 8, 2014
P2a, N=100, Active, not recruiting, Sponsor: AstraZeneca
N=100 --> 224 Recruiting --> Active, not recruiting
- ||| AMG 108 / AstraZeneca
Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 17, 2014
P2a, N=100, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting N=150 --> 100
- ||| AMG 108 / AstraZeneca
Enrollment change: A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Mar 30, 2014
P2, N=464, Completed, Sponsor: MedImmune LLC
N=150 --> 100 N=300 --> 464
- |||| AMG 108 / AstraZeneca
Trial completion: A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Mar 30, 2014
P2, N=464, Completed, Sponsor: MedImmune LLC
N=300 --> 464 Active, not recruiting --> Completed
- |||| AMG 108 / AstraZeneca
Enrollment open: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Jun 12, 2013
P2a, N=100, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| AMG 108 / AstraZeneca
New P2a trial: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 22, 2013
P2a, N=100, Recruiting, Sponsor: AstraZeneca
- ||||| AMG 108 / AstraZeneca
New P2 trial: A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Oct 5, 2011
P2, N=464, Completed, Sponsor: MedImmune LLC